COVID-19-associated acute kidney injury
Jump to navigation
Jump to search
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2],Sogand Goudarzi, MD [3]
Synonyms and keywords: COVID-19-associated AKI
Overview
COVID-19 infection can affect many organs and lead to organ failure. Kidneys are vital organs that can be affected by coronavirus. Acute kidney injury (AKI), a sudden deficit in kidney function, is a complication of COVID-19 and associated with a higher risk of mortality. AKI is frequently seen in critically ill patients with pre-existing conditions. Identifying high-risk patients for AKI and regular monitoring of kidney function tests in these patients play a major role in preventing AKI.
Historical Perspective
- Coronavirus disease 2019 (COVID-19) was first detected in December 2019 in Wuhan, Hubei, China.[1]
- Early reports from China revealed no association between COVID-19 and Acute kidney injury. These reports showed AKI was not seen among COVID-19 hospitalized patients and only a mild rise in BUN or creatinine (10.8%) and mild proteinuria (7.2%) developed. [2]
- However, recent study found 75.4% of hospitalized patients with COVID-19 pneumonia developed kidney complications such as hematuria, proteinuria, and AKI. [3]
Classification
Pathophysiology
- Angiotensin-converting enzyme 2 (ACE2), is a primary receptor for SARS-CoV-2 entry into cells, mostly presents in renal tubular epithelial cells as well as lungs and heart.[5]
- Kidney injury following COVID-19 infection is less frequent than severe lung injury, however ACE2:ACE ratio is higher in the kidneys compared to the respiratory system. (1:1 in the kidneys VS 1:20 in the respiratory system)[5]
- After SARS-CoV-2 enters through the nasal cavity, it may travel to the kidneys and enter the bloodstream leading to severe inflammatory response activation and cytokine storm.
- Cytokine induced AKI may occur due to intrarenal inflammation, hyperpermeability of vessels, hypovolemia and cardiomyopathy, leading to cardiorenal syndrome type 1 that is characterized by third space volume overload such as pleural effusion, edema and intravascular volume loss (hypovolemia) and hypotension.[6]
- cardiomyopathy and COVID-19-associated myocarditis can lead to hypotension and reduction in renal perfusion.
- The major cytokine is IL-6, which induces inflammation and lung endothelial cell injury, leading to ARDS and hypoxia that subsequently cause renal tubular cell injury and AKI. [7][6]
- Cytokine induced AKI may occur due to intrarenal inflammation, hyperpermeability of vessels, hypovolemia and cardiomyopathy, leading to cardiorenal syndrome type 1 that is characterized by third space volume overload such as pleural effusion, edema and intravascular volume loss (hypovolemia) and hypotension.[6]
- To conclude, COVID-19-associated AKI can occur as a result of:[5]
- Sepsis and cytokine storm
- Hypovolemia and Hypotension
- Hypoxemia
- Blood clots formation due to hypercoagulable state, leading to impaired blood flow in the renal arterioles.
Causes
- COVID-19 associated AKI may be caused by SARS-CoV-2, which has a Kidney tropism.
- Recent study found SARS-CoV-2 antigens in renal tubules which suggests the direct damage of SARS-CoV-2 on the kidneys.[8]
Differentiating COVID-19-associated acute kidney injury from other Diseases
- COVID-19-associated AKI must be differentiated from other diseases that cause AKI, such as congestive heart failure, hemorrhage, dehydration, liver failure, urinary tract obstruction, Interstitial nephritis, glomerulonephritis and nephrotoxic medications.
To review the differential diagnosis of AKI, click here.
Epidemiology and Demographics
- The prevalence of AKI among patients with COVID-19 hospitalized in ICU is approximately 0.6-29% in China [11] and 22.2% in the USA.[12]
- Approximately 43% of critically ill patients with COVID-19 developed AKI during the admission period. [4]
- In a cohort study on 99 patients with severe COVID-19, AKI was reported in 42 patients (42.9%) and among them 32 (74.4%) patients had severe AKI (stage III based on KDIGO definition). [13]
- The actual incidence of AKI in critcally ill patients with COVID-19 is uncertain but estimated between 27-85%. "Acute Kidney Injury in COVID-19 Patients | COVID-19".
- Differences of AKI prevalence among studies could be related to several factors, including:[13]
- Patient characteristics
- Comorbidities
- smoking history
- Medications history
- Race
- Severity of COVID-19
- Differences of COVID-19 management among countries
- Patient characteristics
- AKI commonly affects elderly. The incidence of AKI increases with age; the mean age at diagnosis is 57.1 years. [4]
- Men are more commonly affected and have higher risk of COVID-19 complications. [14]
- 57.1% of AKI cases following COVID-19 were male.[4]
Risk Factors
- The most potent risk factors in the development of COVID-19 associated AKI include:[15] [16]
- Elderly
- Age>60 years
- Comorbidities
- Elderly
Screening
Natural History, Complications, and Prognosis
Natural History
- AKI is more likely to develop in the late stages of COVID-19 in critically ill patients.[17]
- Severe COVID-19 pneumonia and severe acute respiratory distress syndrome are associated with developing AKI.[3]
Diagnosis
Diagnostic Study of Choice
- The diagnosis of AKI is based on the KDIGO criteria, which includes:[18]
- Elevated serum Creatinine by β₯0.3 mg/dl (β₯26.5 ΞΌmol/l) within 48 hours; or
- Elevated serum Creatinine to β₯1.5 times baseline within the previous 7 days; or
- Urine volume < 0.5 ml/kg/h for >6 hours
Symptoms
- COVID-19-associated AKI commonly occurs between 5 to 9 days after hospitalization. [13]
- Patients in the early stages of kidney failure may be asymptomatic.
- If left untreated, patients may progress to develop Azotemia and Uremia, which occur due to the buildup of waste materials in the blood.
- Symptoms of kidney injury include [19]:
Physical Examination
- Physical examination of patients with AKI is usually remarkable for[19]:
- Signs of dehydration, such as tachycardia, tachypnea, hypotension, and dry mucosa
- Fluid retention, leading to edema and swelling of periorbital and extremities
- Confusion due to severe dehydration and electrolyte imbalances
- Decrease in urine output:Oliguria or Anuria
- cardiac arrhythmia due to electrolyte imbalances such as high level of Potassium
Laboratory Findings
- Laboratory findings consistent with the diagnosis of COVID-19-associated AKI include[20]:
- Elevated serum creatinine
- Elevated BUN level
- Plasma BUN-creatinine ratio> 20 in prerenal AKI
- Plasma BUN-creatinine ratio< 15 in intrinsic AKI or acute tubular necrosis
- Fractional excretion of sodium (FENa)
- Urinary sediment
- Hyaline casts in prerenal AKI
- Granular or Muddy brown casts in intrinsic AKI or acute tubular necrosis
- Several biomarkers have been found to diagnose and predict AKI that include: [21][22][23]
Electrocardiogram
- There are no specific ECG findings associated with AKI. However, electrolyte disturbances such as hyperkalemia might lead to various ECG abnormalities.
X-ray
- There are no x-ray specific findings associated with AKI. However, X-ray may be used in the diagnosis of AKI associated volume overload.
- To view the x-ray finidings on COVID-19, click here.
Echocardiography or Ultrasound
- Ultrasound may be helpful in the diagnosis of AKI. Findings on ultrasound suggestive of AKI include hydrenephrosis and reduced renal blood flow.[24]
CT scan
- There are no CT scan findings associated with AKI.
- To view the CT scan findings on COVID-19, click here.
MRI
- There are no MRI findings associated with AKI.
- To view the MRI findings on COVID-19, click here.
Other Imaging Findings
- 99m Technetium (Tc) scan may be helpful in the diagnosis of AKI, which shows reduced renal blood flow and tubular function.[24]
- To view other imaging findings on COVID-19, click here.
Other Diagnostic Studies
- There are no other diagnostic studies associated with AKI.
- To view other diagnostic studies for COVID-19, click here.
Treatment
Medical Therapy
- Management of AKI following COVID-19 includes antiviral therapies, identifying electrolyte disorders, and intravenous fluid resuscitation.[17]
- Treatment of AKI following COVID-19 includes:[17] [16]
- Correction of hypovolemia and hypotension by the administration of adequate intravenous fluid
- Isotonic crystalloid is recommended among all patients who develop AKI. [18]
- Correction of electrolyte disorders
- antiviral therapy:
- Recently, Remdesivir has been found effective against COVID-19. [25]
- Anticoagulants in hypercoagulable conditions
- Loop diuretics
- In volume overload conditions
- Diuretics should not be used regularly as they predispose patients to volume depletion.
- Correction of hypovolemia and hypotension by the administration of adequate intravenous fluid
Interventions
- renal replacement therapy is recommended among patients with AKI who develop [26]
- volume overload
- severe metabolic acidosis
- refractory hyperkalemia
- uremic complications
- If AKI is unresponsive to supportive therapy
- in hemodynamically unstable patients
- The dialysis of choice in hemodynamically unstable patients with COVID-19 is continuous venovenous hemodialysis.
- renal replacement therapy is associated with hypercoagulation.[16]
- To view COVID-19-associated hemodialysis, click here.
- Sequential extracorporeal therapy
- It removes cytokines, which reduces systemic inflammation and subsequent organ failure.[17]
Surgery
Surgical intervention is not recommended for the management of COVID-19 associated AKI.
Primary Prevention
- Effective measures for the primary prevention of AKI include:[27]
- Volume resuscitation
- Patients with COVID-19 should be evaluated for intravascular volume status based on physical examination and fluid balance.[16]
- Isotonic saline is recommended as a prevention strategy for patients who are at increased risk for AKI by expanding intravascular volume. [18]
- Monitoring renal function tests
- Serial monitoring of BUN, serum creatinine, and electrolytes such as sodium, potassium and bicarbonate should be considered frequently every 48 hours or more in high risk patients.[16]
- Avoidance of drugs and nephrotoxins in high risk patients[28]
- Volume resuscitation
Secondary Prevention
- Effective measures for the secondary prevention of AKI is using biomarkers for early diagnosis and treatment of AKI in early stages before it causes significant complications.[29][21]
References
- β Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global healthβThe latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases. 91: 264β266. doi:10.1016/j.ijid.2020.01.009. PMC 7128332 Check
|pmc=value (help). PMID 31953166. - β Wang, Luwen; Li, Xun; Chen, Hui; Yan, Shaonan; Li, Dong; Li, Yan; Gong, Zuojiong (2020). "Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China". American Journal of Nephrology. 51 (5): 343β348. doi:10.1159/000507471. ISSN 0250-8095.
- β 3.0 3.1 3.2 Pei, Guangchang; Zhang, Zhiguo; Peng, Jing; Liu, Liu; Zhang, Chunxiu; Yu, Chong; Ma, Zufu; Huang, Yi; Liu, Wei; Yao, Ying; Zeng, Rui; Xu, Gang (2020). "Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia". Journal of the American Society of Nephrology. 31 (6): 1157β1165. doi:10.1681/ASN.2020030276. ISSN 1046-6673.
- β 4.0 4.1 4.2 4.3 Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C; et al. (2020). "Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia". J Am Soc Nephrol. 31 (6): 1157β1165. doi:10.1681/ASN.2020030276. PMC 7269350 Check
|pmc=value (help). PMID 32345702 Check|pmid=value (help). - β 5.0 5.1 5.2 5.3 Malha, Line; Mueller, Franco B.; Pecker, Mark S.; Mann, Samuel J.; August, Phyllis; Feig, Peter U. (2020). "COVID-19 and the Renin-Angiotensin System". Kidney International Reports. 5 (5): 563β565. doi:10.1016/j.ekir.2020.03.024. ISSN 2468-0249.
- β 6.0 6.1 6.2 Ronco C, Reis T (2020). "Kidney involvement in COVID-19 and rationale for extracorporeal therapies". Nat Rev Nephrol. 16 (6): 308β310. doi:10.1038/s41581-020-0284-7. PMC 7144544 Check
|pmc=value (help). PMID 32273593 Check|pmid=value (help). - β Husain-Syed F, Slutsky AS, Ronco C (2016). "Lung-Kidney Cross-Talk in the Critically Ill Patient". Am J Respir Crit Care Med. 194 (4): 402β14. doi:10.1164/rccm.201602-0420CP. PMID 27337068.
- β https://www.medrxiv.org/content/10.1101/2020.03.04.20031120v4. Missing or empty
|title=(help) - β Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D (2006). "Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes". J Am Soc Nephrol. 17 (11): 3067β75. doi:10.1681/ASN.2006050423. PMID 17021266.
- β Perico L, Benigni A, Remuzzi G (2020). "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade". Nephron. 144 (5): 213β221. doi:10.1159/000507305. PMC 7179544 Check
|pmc=value (help). PMID 32203970 Check|pmid=value (help). - β "Acute Kidney Injury in COVID-19 Patients | COVID-19".
- β Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; et al. (2020). "Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area". JAMA. doi:10.1001/jama.2020.6775. PMC 7177629 Check
|pmc=value (help). PMID 32320003 Check|pmid=value (help). - β 13.0 13.1 13.2 Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L (2020). "Acute kidney injury in critically ill patients with COVID-19". Intensive Care Med. 46 (7): 1339β1348. doi:10.1007/s00134-020-06153-9. PMC 7290076 Check
|pmc=value (help). PMID 32533197 Check|pmid=value (help). - β Sharma G, Volgman AS, Michos ED (2020). "Sex Differences in Mortality from COVID-19 Pandemic: Are Men Vulnerable and Women Protected?". JACC Case Rep. doi:10.1016/j.jaccas.2020.04.027. PMC 7198137 Check
|pmc=value (help). PMID 32373791 Check|pmid=value (help). - β Rabb H (2020). "Kidney diseases in the time of COVID-19: major challenges to patient care". J Clin Invest. 130 (6): 2749β2751. doi:10.1172/JCI138871. PMC 7259985 Check
|pmc=value (help). PMID 32250968 Check|pmid=value (help). - β 16.0 16.1 16.2 16.3 16.4 16.5 Selby NM, Forni LG, Laing CM, Horne KL, Evans RD, Lucas BJ; et al. (2020). "Covid-19 and acute kidney injury in hospital: summary of NICE guidelines". BMJ. 369: m1963. doi:10.1136/bmj.m1963. PMID 32457068 Check
|pmid=value (help). - β 17.0 17.1 17.2 17.3 17.4 Ronco C, Reis T, Husain-Syed F (2020). "Management of acute kidney injury in patients with COVID-19". Lancet Respir Med. doi:10.1016/S2213-2600(20)30229-0. PMC 7255232 Check
|pmc=value (help). PMID 32416769 Check|pmid=value (help). - β 18.0 18.1 18.2 Khwaja A (2012). "KDIGO clinical practice guidelines for acute kidney injury". Nephron Clin Pract. 120 (4): c179β84. doi:10.1159/000339789. PMID 22890468.
- β 19.0 19.1 Skorecki K, Green J, Brenner BM (2005). "Chronic renal failure". In Kasper DL, Braunwald E, Fauci AS, et al. Harrison's Principles of Internal Medicine (16th ed.). New York, NY: McGraw-Hill. pp. 1653β63. ISBN 978-0-07-139140-5.
- β Ostermann, Marlies; Joannidis, Michael (2016). "Acute kidney injury 2016: diagnosis and diagnostic workup". Critical Care. 20 (1). doi:10.1186/s13054-016-1478-z. ISSN 1364-8535.
- β 21.0 21.1 Kashani K, Cheungpasitporn W, Ronco C (2017). "Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption". Clin Chem Lab Med. 55 (8): 1074β1089. doi:10.1515/cclm-2016-0973. PMID 28076311.
- β Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM (2017). "Biomarkers in acute kidney injury - pathophysiological basis and clinical performance". Acta Physiol (Oxf). 219 (3): 554β572. doi:10.1111/apha.12764. PMC 5575831. PMID 27474473.
- β Oh DJ (2020). "A long journey for acute kidney injury biomarkers". Ren Fail. 42 (1): 154β165. doi:10.1080/0886022X.2020.1721300. PMC 7034110 Check
|pmc=value (help). PMID 32050834 Check|pmid=value (help). - β 24.0 24.1 Kalantarinia K (2009). "Novel imaging techniques in acute kidney injury". Curr Drug Targets. 10 (12): 1184β9. doi:10.2174/138945009789753246. PMC 2891573. PMID 19715540.
- β Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A; et al. (2020). "Compassionate Use of Remdesivir for Patients with Severe Covid-19". N Engl J Med. 382 (24): 2327β2336. doi:10.1056/NEJMoa2007016. PMC 7169476 Check
|pmc=value (help). PMID 32275812 Check|pmid=value (help). - β National Kidney Foundation (2015). "KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update". Am J Kidney Dis. 66 (5): 884β930. doi:10.1053/j.ajkd.2015.07.015. PMID 26498416.
- β Kellum, John A; Leblanc, Martine; Gibney, R T. Noel; Tumlin, James; Lieberthal, Wilfred; Ronco, Claudio (2006). "Primary prevention of acute renal failure in the critically ill". Current Opinion in Internal Medicine. 5 (1): 74β78. doi:10.1097/01.ccx.0000179934.76152.02. ISSN 1535-5942.
- β Lameire, N.; Van Biesen, W.; Hoste, E.; Vanholder, R. (2008). "The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI". Clinical Kidney Journal. 1 (6): 392β402. doi:10.1093/ndtplus/sfn162. ISSN 2048-8505.
- β Pickering JW, Endre ZH (2009). "Secondary prevention of acute kidney injury". Curr Opin Crit Care. 15 (6): 488β97. doi:10.1097/MCC.0b013e328332f66f. PMID 19823082.